TMCnet News

Correction: Fitch Rates Merck's Euro Notes Offering 'A'
[October 27, 2016]

Correction: Fitch Rates Merck's Euro Notes Offering 'A'


(This is a correction of a release issued Oct. 27, 2016. It clarifies that Merck's existing ratings were not affirmed as was stated in the original release.)

Fitch Ratings has assigned an 'A' rating to Merck & Co., Inc.'s (MRK/Merck) euro notes offering. A complete list of ratings follows at the end of this press release.

KEY RATING DRIVERS

The company's 'A' rating reflects the following:

--Recently introduced therapies, an advancing pipeline and manageable patent expiries should support intermediate- to long-term growth.

--Fitch believes that Merck will pursue targeted acquisitions as opposed to large transformative ones. An improving pipeline and narrowing strategic focus reduces the need to do big deals.

--Fitch expects Merck will continue favor share repurchases to deleveraging, with the possibility of further debt-funded stock buybacks.

--Fitch forecasts that Merck will generate solid FCF during the forecast period supported by improving margins and moderate revenue growth.

New Products/ Growth Opportunities: Products approved during the last three years should help to drive intermediate- to long-term, top-line growth for Merck. Most importantly, Keytruda (skin and lung cancer) is gaining traction in the market, supported by an ongoing stream of clinical data, but facing competition from a Bristol-Myers product and potentially similar drugs that may receive approval during the next few years. Merck is also evaluating Keytruda's safety and efficacy in other cancers and in combination with other oncolytics. Bridion (post-surgical recovery), Belsomra (insomnia), Grastek (allergies) and Rawitek (allergies) are unique-acting therapies, which should provide these two drugs competitive positions. Zontivitiy (cardiovascular) and Zepatier (hepatitis C) have entered increasingly crowded segments but should be able to gain some share from both newer and older treatments.

Expanding Late-Stage Pipeline: Fitch expects Merck to continue to build its late-stage pipeline with new molecular entities (NMEs) to treat cancers, bacterial and viral infections, diabetes, cardiovascular disorders, central nervous afflictions, osteoporosis, and other diseases. While the majority of these projects are internally developed, Merck has partnered with other innovator firms to take advantage of technological advancements that were discovered externally. The landscape for drug development is expanding, particularly as developers learn more about how genetics influence the development, prevention and treatment of disease. As such, Fitch believes that it is responsible and strategically advantageous for firms to look externally as well as internally regarding new drug development.

Patent Exposure Manageable: The company has and will continue to face some significant patent expiries during the next year, but Fitch views the risk as manageable with roughly 18% of total firm sales are at risk. In addition, Remicade, which accounts for about 4.2% of total firm sales, is a biologic that has experienced less rapid sales losses to generic competition compared to traditional small-molecule pharmaceuticals. Vytorin and Zetia, however, are small molecules and account for roughly 10% of total revenues. Fitch expects these two products will lose significant sales shortly after their patents expire, as is typically the case for small-molecule drugs.

Solid Free Cash Flow Expected: Fitch forecasts that Merck will generate $5.7 billion - $5.9 billion in free cash flow (FCF) during 2016. Improving margins driven by an improving sales mix and strong cost control should more than offset expected soft near-term, top-line growth. Fitch expects FCF to incrementally increase during the multi-year forecast period.

Targeted Acquisition Most Likely: Fitch looks for Merck to pursue mainly targeted acquisitions in the intermediate term. The company has improved its operational and financial prospects through successfully gaining regulatory approvals on late-stage pipeline projects and has continued to back fill its pipeline with new and advancing projects. An improved growth and profitability profile decreases the need for the company to execute large strategic business combinations.

Share Repurchases to Continue: Fitch assumes continued shareholder friendly actions during the near term, some of which the company may fund with debt. Merck has occasionally funded its share repurchases with debt. During 2015, the company purchased a net $3.7 billion of its common stock, compared to $6.1 billion during the prior LTM period. The repurchases were executed under a $15 billion program authorized in May 2013 as well as an additional $10 billion authorized in March 2015. As of June 30, 2016, the 2013 allotment was fully utilized, with $6.9 billion remaining on the $10 billion extension.

KEY ASSUMPTIONS

Fitch's key assumptions within the rating case for Merck's 'A' rating include the following:

--Incrementally increasing revenue during the forecast period, driven by newer products, largely offset in the near term by foreign exchange headwinds and select product patent expirations.

--EBITDA operating margin improvement driven by a focus on costs and an improving sales mix.

--Annual FCF (cash flow from operations minus capital expenditures minus dividends) of roughly $5.9 billion during 2016.

--Targeted acquisitions prioritized over strategic, transformative transactions.

--Continued significant share repurchases.

--Leverage to range between 1.7x - 1.9x during the next two years.

RATING SENSITIVITIES

Positive: Future developments that may, individually or collectively, lead to positive rating action include the following:

--Improving operations including new product development that support long-term positive revenue growth and margin stability/icreases;



--An operational profile that would consistently generate significantly positive FCF;

--Cash deployment strategy that maintains gross debt leverage below 1.7x, including managing through operational stress such as patent expiries.


Negative: Future developments that may, individually or collectively, lead to negative rating action include the following:

--Material and lasting deterioration in operations and FCF, possibly driven by patent expiries not being offset by new product development;

--Leveraging acquisitions without the prospect of timely debt/leverage reduction;

--Persistent leverage above 2.2x.

LIQUIDITY

Adequate Liquidity: Fitch looks for Merck to maintain adequate liquidity through strong FCF generation and ample access to the credit markets. FCF for the LTM ending June 30, 2016 was $4.7 billion. At the end of the period, Merck had approximately $11.8 billion in cash/short-term investments (U.S.: 10% - 20% of total balances/OUS: 80% - 90% of total balances) and full availability on its $6 billion revolver, maturing in August 2019.

Manageable Debt Maturities: As of June 30, 2016, the company had $24.1 billion in debt outstanding, with $234 million maturing in 2016, $317 million in 2017, $3 billion in 2018 and $1.3 billion in 2019. Fitch expects near- to mid-term maturities will be satisfied primarily through refinancing in the public debt markets.

FULL LIST OF RATINGS

Fitch currently rates Merck as follows:

Merck & Co., Inc.

--Long-Term Issuer Default Rating (IDR) 'A';

--Senior unsecured credit facility 'A';

--Senior unsecured debt 'A';

--Short-Term IDR 'F1';

--Commercial paper 'F1'.

The Rating Outlook is Stable.

Summary of Financial Statement Adjustments - Financial statement adjustments that depart materially from those contained in the published financial statements of the relevant rated entity or obligor are disclosed below:

--Historical and projected EBITDA is adjusted to add back non-cash stock based compensation. During the LTM period ended March 31, 2016, Fitch added back $304 million in non-cash stock based compensation to its EBITDA calculation and $214 million in restructuring costs to gross profit.

Date of Relevant Committee: July 7, 2016

Additional information is available on www.fitchratings.com.

Applicable Criteria

Corporate Rating Methodology - Including Short-Term Ratings and Parent and Subsidiary Linkage - Effective from 17 August 2015 to 27 September 2016 (pub. 17 Aug 2015)

https://www.fitchratings.com/site/re/869362

Additional Disclosures

Solicitation Status

https://www.fitchratings.com/gws/en/disclosure/solicitation?pr_id=1013890

Endorsement Policy

https://www.fitchratings.com/regulatory

ALL FITCH CREDIT RATINGS ARE SUBJECT TO CERTAIN LIMITATIONS AND DISCLAIMERS. PLEASE READ THESE LIMITATIONS AND DISCLAIMERS BY FOLLOWING THIS LINK: HTTPS://WWW.FITCHRATINGS.COM/UNDERSTANDINGCREDITRATINGS. IN ADDITION, RATING DEFINITIONS AND THE TERMS OF USE OF SUCH RATINGS ARE AVAILABLE ON (News - Alert) THE AGENCY'S PUBLIC WEB SITE AT WWW.FITCHRATINGS.COM. PUBLISHED RATINGS, CRITERIA, AND METHODOLOGIES ARE AVAILABLE FROM THIS SITE AT ALL TIMES. FITCH'S CODE OF CONDUCT, CONFIDENTIALITY, CONFLICTS OF INTEREST, AFFILIATE FIREWALL, COMPLIANCE, AND OTHER RELEVANT POLICIES AND PROCEDURES ARE ALSO AVAILABLE FROM THE CODE OF CONDUCT SECTION OF THIS SITE. FITCH MAY HAVE PROVIDED ANOTHER PERMISSIBLE SERVICE TO THE RATED ENTITY OR ITS RELATED THIRD PARTIES. DETAILS OF THIS SERVICE FOR RATINGS FOR WHICH THE LEAD ANALYST IS BASED IN AN EU-REGISTERED ENTITY CAN BE FOUND ON THE ENTITY SUMMARY PAGE FOR THIS ISSUER ON THE FITCH WEBSITE.

Copyright © 2016 by Fitch Ratings, Inc., Fitch Ratings Ltd. and its subsidiaries. 33 Whitehall Street, NY, NY 10004. Telephone: 1-800-753-4824, (212) 908-0500. Fax: (212) 480-4435. Reproduction or retransmission in whole or in part is prohibited except by permission. All rights reserved. In issuing and maintaining its ratings and in making other reports (including forecast information), Fitch relies on factual information it receives from issuers and underwriters and from other sources Fitch believes to be credible. Fitch conducts a reasonable investigation of the factual information relied upon by it in accordance with its ratings methodology, and obtains reasonable verification of that information from independent sources, to the extent such sources are available for a given security or in a given jurisdiction. The manner of Fitch's factual investigation and the scope of the third-party verification it obtains will vary depending on the nature of the rated security and its issuer, the requirements and practices in the jurisdiction in which the rated security is offered and sold and/or the issuer is located, the availability and nature of relevant public information, access to the management of the issuer and its advisers, the availability of pre-existing third-party verifications such as audit reports, agreed-upon procedures letters, appraisals, actuarial reports, engineering reports, legal opinions and other reports provided by third parties, the availability of independent and competent third- party verification sources with respect to the particular security or in the particular jurisdiction of the issuer, and a variety of other factors. Users of Fitch's ratings and reports should understand that neither an enhanced factual investigation nor any third-party verification can ensure that all of the information Fitch relies on in connection with a rating or a report will be accurate and complete. Ultimately, the issuer and its advisers are responsible for the accuracy of the information they provide to Fitch and to the market in offering documents and other reports. In issuing its ratings and its reports, Fitch must rely on the work of experts, including independent auditors with respect to financial statements and attorneys with respect to legal and tax matters. Further, ratings and forecasts of financial and other information are inherently forward-looking and embody assumptions and predictions about future events that by their nature cannot be verified as facts. As a result, despite any verification of current facts, ratings and forecasts can be affected by future events or conditions that were not anticipated at the time a rating or forecast was issued or affirmed.

The information in this report is provided "as is" without any representation or warranty of any kind, and Fitch does not represent or warrant that the report or any of its contents will meet any of the requirements of a recipient of the report. A Fitch rating is an opinion as to the creditworthiness of a security. This opinion and reports made by Fitch are based on established criteria and methodologies that Fitch is continuously evaluating and updating. Therefore, ratings and reports are the collective work product of Fitch and no individual, or group of individuals, is solely responsible for a rating or a report. The rating does not address the risk of loss due to risks other than credit risk, unless such risk is specifically mentioned. Fitch is not engaged in the offer or sale of any security. All Fitch reports have shared authorship. Individuals identified in a Fitch report were involved in, but are not solely responsible for, the opinions stated therein. The individuals are named for contact purposes only. A report providing a Fitch rating is neither a prospectus nor a substitute for the information assembled, verified and presented to investors by the issuer and its agents in connection with the sale of the securities. Ratings may be changed or withdrawn at any time for any reason in the sole discretion of Fitch. Fitch does not provide investment advice of any sort. Ratings are not a recommendation to buy, sell, or hold any security. Ratings do not comment on the adequacy of market price, the suitability of any security for a particular investor, or the tax-exempt nature or taxability of payments made in respect to any security. Fitch receives fees from issuers, insurers, guarantors, other obligors, and underwriters for rating securities. Such fees generally vary from US$1,000 to US$750,000 (or the applicable currency equivalent) per issue. In certain cases, Fitch will rate all or a number of issues issued by a particular issuer, or insured or guaranteed by a particular insurer or guarantor, for a single annual fee. Such fees are expected to vary from US$10,000 to US$1,500,000 (or the applicable currency equivalent). The assignment, publication, or dissemination of a rating by Fitch shall not constitute a consent by Fitch to use its name as an expert in connection with any registration statement filed under the United States securities laws, the Financial Services and Markets Act of 2000 of the United Kingdom, or the securities laws of any particular jurisdiction. Due to the relative efficiency of electronic publishing and distribution, Fitch research may be available to electronic subscribers up to three days earlier than to print subscribers.

For Australia, New Zealand, Taiwan and South Korea only: Fitch Australia Pty Ltd holds an Australian financial services license (AFS license no. 337123) which authorizes it to provide credit ratings to wholesale clients only. Credit ratings information published by Fitch is not intended to be used by persons who are retail clients within the meaning of the Corporations Act 2001


[ Back To TMCnet.com's Homepage ]